NASDAQ:NGM
NGM Biopharmaceuticals Inc. Stock News
$1.54
+0 (+0%)
At Close: May 16, 2024
NGM Bio to Present at Three Upcoming Investor Conferences
08:00am, Wednesday, 11'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti
NGM Bio Aldafermin Data, And Other News: The Good, Bad And Ugly Of Biopharma
06:52am, Sunday, 06'th Sep 2020
NGM Bio reports positive Phase 2 data for Aldafermin. CorMedix Inc.
NGM Biopharmaceuticals (NGM) Investor Presentation - Slideshow
03:17pm, Monday, 31'st Aug 2020
The following slide deck was published by NGM Biopharmaceuticals, Inc. in conjunction with this event..
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
08:30am, Saturday, 15'th Aug 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Viking Therapeutics: Another Year In Review
02:39pm, Thursday, 13'th Aug 2020
Recently announced Q2'20 financial results and provided key updates on development timelines. Filed IND for VK0214 in X-ALD.
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
09:45pm, Wednesday, 12'th Aug 2020
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -15.15% and -3.25%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results
08:05pm, Wednesday, 12'th Aug 2020
\--Sustained progress across clinical development programs spanning liver, retinal and metabolic diseases and cancer--\--Aldafermin continues to advance toward late-stage clinical development in non-
NGM Biopharmaceuticals (NASDAQ:NGM) Is In A Good Position To Deliver On Growth Plans
02:30pm, Tuesday, 11'th Aug 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
02:26pm, Tuesday, 11'th Aug 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Why Earnings Season Could Be Great for NGM Biopharmaceuticals (NGM)
12:30pm, Friday, 07'th Aug 2020
NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NGM Biopharmaceuticals (NYSE:NGM) Director Acquires $13,168.68 in Stock
07:04am, Wednesday, 05'th Aug 2020
NGM Biopharmaceuticals (NYSE:NGM) Director Group L. P. Column purchased 732 shares of the stock in a transaction on Thursday, July 30th. The shares were purchased at an average cost of $17.99 per shar
Analysts Estimate NGM Biopharmaceuticals (NGM) to Report a Decline in Earnings: What to Look Out for
04:31pm, Monday, 03'rd Aug 2020
NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NGM Bio to Present at Two Upcoming Investor Conferences
12:00pm, Friday, 31'st Jul 2020
SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti
\-- Multicenter, randomized, double-masked, sham-controlled study will evaluate safety and efficacy of intravitreal injections of NGM621 every four or eight weeks for 48 weeks --\-- GA is a progress
